Hallman M, Järvenpää A L, Pohjavuori M
Arch Dis Child. 1986 Nov;61(11):1076-83. doi: 10.1136/adc.61.11.1076.
We report a randomised double blind trial of myo-inositol (inositol) supplementation for 10 days in 74 preterm infants with a birth weight less than 2000 g (mean gestational age 29.5 weeks and mean birth weight 1266 g). All infants required artificial ventilation for treatment of respiratory distress syndrome. Inositol (120-160 mg/kg/day) was administered by the ingastric or intravenous route. The 37 infants who received inositol supplementation required less mechanical ventilation during days 4-10, had less failures of indomethacin to close ductus arteriosus, and had less deaths or bronchopulmonary dysplasia, or both, than the infants treated with placebo. There were no detectable adverse effects. These preliminary results suggest that inositol is an important nutrient in immature preterm infants.
我们报告了一项针对74名出生体重低于2000克（平均胎龄29.5周，平均出生体重1266克）的早产婴儿进行的为期10天的肌醇补充剂随机双盲试验。所有婴儿均因呼吸窘迫综合征需要人工通气治疗。肌醇（120 - 160毫克/千克/天）通过胃内或静脉途径给药。与接受安慰剂治疗的婴儿相比，接受肌醇补充剂的37名婴儿在第4 - 10天需要的机械通气更少，吲哚美辛关闭动脉导管未闭的失败情况更少，死亡或支气管肺发育不良（或两者兼有）的情况也更少。未发现可检测到的不良反应。这些初步结果表明，肌醇是未成熟早产儿的一种重要营养素。
